X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Update

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) saw a large decrease in short interest in February. As of February 15th, there was short interest totalling 11,060,000 shares, a decrease of 33.4% from the January 31st total of 16,610,000 shares. Based on an average daily volume of 4,110,000 shares, the short-interest ratio is presently 2.7 days.

Analyst Ratings Changes

XFOR has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and issued a $1.50 target price on shares of X4 Pharmaceuticals in a research report on Friday, February 7th. Stifel Nicolaus reduced their price objective on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, November 14th.

X4 Pharmaceuticals Stock Performance

Shares of XFOR opened at $0.36 on Tuesday. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. X4 Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $1.60. The firm has a market cap of $61.43 million, a PE ratio of -4.00 and a beta of 0.12. The stock’s fifty day moving average price is $0.56 and its two-hundred day moving average price is $0.57.

Insider Activity at X4 Pharmaceuticals

In other news, CFO Adam S. Mostafa sold 74,773 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $33,647.85. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Paula Ragan sold 76,473 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $34,412.85. Following the sale, the chief executive officer now directly owns 1,087,386 shares in the company, valued at approximately $489,323.70. This trade represents a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 202,663 shares of company stock worth $91,198. Company insiders own 1.62% of the company’s stock.

Institutional Trading of X4 Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in XFOR. GSA Capital Partners LLP purchased a new position in shares of X4 Pharmaceuticals in the 3rd quarter worth about $340,000. Verition Fund Management LLC bought a new position in X4 Pharmaceuticals during the 3rd quarter valued at approximately $30,000. Point72 Asset Management L.P. increased its position in X4 Pharmaceuticals by 15.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 625,052 shares of the company’s stock valued at $418,000 after buying an additional 81,968 shares in the last quarter. State Street Corp boosted its stake in X4 Pharmaceuticals by 6.8% during the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock valued at $1,976,000 after purchasing an additional 189,105 shares during the last quarter. Finally, Jane Street Group LLC boosted its stake in X4 Pharmaceuticals by 103.4% during the 3rd quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock valued at $166,000 after purchasing an additional 126,296 shares during the last quarter. 72.03% of the stock is currently owned by institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.